GLP-1 Receptor Agonist and DPP IV Inhibitor in the Treatment of Type-2 Diabetes
Conference: HBDSS 2022 - 2nd International Conference on Health Big Data and Smart Sports
10/28/2022 - 10/30/2022 at Xiamen, China
Proceedings: HBDSS 2022
Pages: 5Language: englishTyp: PDF
Authors:
Du, Wei (China Pharmaceutical University, Nanjing, China)
Cao, Hongxia (Nanjing University of Information Science & Technology, Nanjing, China)
Abstract:
Diabetes mellitus is a kind of metabolic diseases typified by hyperglycemia. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. In 2021, 6.7 million people had been deprived of life by diabetes worldwide. Many new drugs to treat diabetes have been devised like the sulfonylurea, metformin. GLP-1 agonists and DPP-4 inhibitors are a new generation of antidiabetic drugs. This article review some literatureand give a brief summary of this two kinds drugs about their characteristics, side effects, cautions and combination recommendation. Comparison in terms of effectiveness, economy, safety are also given to give more detailed help to clinical treatment.